Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ifinatamab deruxtecan + pembrolizumab + 5-fluorouracil + leucovorin + oxaliplatin
- Development stage
- Phase 2
- Lead developer
- Daiichi Sankyo
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination is an experimental multi-agent regimen evaluated in clinical trials, particularly for esophageal squamous cell carcinoma. It combines ifinatamab deruxtecan (an antibody-drug conjugate targeting B7-H3), pembrolizumab (a PD-1 checkpoint inhibitor), and a chemotherapeutic backbone including 5-fluorouracil, leucovorin, and oxaliplatin. Ifinatamab deruxtecan delivers a cytotoxic deruxtecan payload directly to cells expressing B7-H3. Pembrolizumab blocks the PD-1 pathway to enhance T-cell-mediated antitumor response. The chemotherapy agents (5-fluorouracil, leucovorin, oxaliplatin) act by damaging DNA or interfering with DNA synthesis, contributing to cytotoxic effects against rapidly dividing tumor cells. The combination is studied primarily for advanced esophageal squamous cell carcinoma, aiming to improve efficacy over existing treatment regimens[1][3][5].
- Other names
- ifinatamab deruxtecanpembrolizumab5-fluorouracilleucovorinoxaliplatin
02
Targets
B7-H3DNAPDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on ifinatamab deruxtecan + pembrolizumab + 5-fluorouracil + leucovorin + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ifinatamab deruxtecan + pembrolizumab + 5-fluorouracil + leucovorin + oxaliplatin.